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The prevalence of cardiovascular disease (CVD), the leading cause of death in the US, is
predicted to increase due to the shift in age of the general population and increase in CVD
risk factors such as obesity and diabetes. New therapies are required to decrease the
prevalence of CVD risk factors (obesity and diabetes) as well as reduce atherothrombosis,
the major cause of CVD related mortality. Oxylipins, bioactive metabolites derived from
the oxygenation of polyunsaturated fatty acids, play a role in the progression of CVD risk
factors and thrombosis. Aspirin, a cyclooxygenase-1 inhibitor, decreases atherothrombotic
associated mortality by 25%. These potent effects of aspirin have shown the utility of
modulating oxylipin signaling pathways to decrease CVD mortality. The role of many
oxylipins in the progression of CVD, however, is still uncertain or controversial. An increased
understanding of the role oxylipins play in CVD risk factors and thrombosis could lead to
new therapies to decrease the prevalence of CVD and its associated mortality.
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In the US, cardiovascular disease (CVD) is responsible for 25%
of all deaths making it the leading cause of mortality (Murphy
et al., 2013). CVD is a group of diseases that affects the heart
or blood vessels including heart failure, hypertension, coronary
artery disease, and cerebral vascular disease. Thrombotic com-
plications of coronary artery and cerebral vascular disease are
largely responsible for the high level of mortality associated with
CVD (Jackson, 2011; Roger et al., 2011) and current anti-platelet
therapy has successfully reduced CVD associated mortality by
approximately 25% (Jackson, 2011; Roger et al., 2011). While
those results are encouraging there is growing concern over the
increase in the population with CVD risk factors such as obesity
and diabetes. Diabetic patients are disproportionately affected by
CVD which is responsible for 65% of patient mortality (Lincoff,
2003). Over 7.7% of the US population is diagnosed with dia-
betes and another 29% is diagnosed as pre-diabetic (Lloyd-Jones
et al., 2010). Hence, newer therapies are required to decrease CVD
risk factors for diabetics. An underutilized therapeutic approach
to treating these diseases is through modulation of oxylipin sig-
naling. Oxylipins are bioactive lipids generated by the oxidation
of polyunsaturated fatty acids (PUFAs). Recent research has des-
ignated a role for oxylipins in both CVD as well as diabetes.
While the cyclooxygenase (COX)-derived oxylipins have been
the focus of many reviews, the goal of this review is to shed
light on the emerging roles of 12-lipoxygenase (12-LOX) in the
pathologies of thrombosis and hemostasis as well as progression of
diabetes.
OXYLIPIN BIOLOGY
Oxylipins follow a general biosynthesis and signaling scheme
(Figure 1). Due to the potency and short half-life of most
oxylipins, they are not stored but synthesized de novo in a
tightly regulated manner (Funk, 2001). In order to restrict
aberrant oxylipin production, the level of free PUFAs are kept
low with the preponderance of PUFAs actively sequestered to
membrane-bound glycerophospholipids by the action of acyl-
transferases and transacylases (Perez-Chacon et al., 2009). Upon
cellular activation, PUFAs in the sn-2 position of membrane
glycerophospholipids are liberated by cytoplasmic phospholi-
pase A2 (PLA2; Ghosh et al., 2006). Free PUFAs are oxygenated
by three families of enzymes COX, lipoxygenase (LOX), and
cytochrome P450 (CYP) into distinct classes of oxylipins (Massey
and Nicolaou, 2013). Subsequently, oxylipins can activate perox-
isome proliferator-activated receptors (PPARs), ligand activated
transcription factors, or diffuse through the plasma membrane
and signal through G protein-coupled receptors (GPCRs) in a
paracrine or autocrinemanner (Shearer andNewman,2009;Wahli
and Michalik, 2012). The type of oxylipins produced depends
predominately on the PUFA being oxidized and the oxygenase
metabolizing the PUFA.
The oxygenation of different PUFAs gives rise to distinct
oxylipins that vary in length and double bond conﬁguration.
These parameters determine the oxylipins three-dimensional spa-
tial conﬁguration and receptor speciﬁcity (Mozaffarian and Wu,
2012). The main oxylipin PUFA precursors [dihomo-gamma-
linolenic acid (DGLA), arachidonic acid (AA), eicosapentaenoic
acid (EPA), and docosahexaenoic acid (DHA)] can be obtained
directly from the diet or from the elongation and desaturation
of linolenic (omega-3, 18:3) and linoleic acid (LA; omega-6,
18:2) and alpha-linolenic acid (ALA), respectively (Massey and
Nicolaou, 2013).
The linoleic acidmetabolismpathway is responsible for the pro-
duction of two main oxylipin precursors, DGLA and AA (Lagarde
et al., 2013). The ﬁrst step in this pathway is the addition of a dou-
ble bond to LA by6 desaturase which produces gamma-linolenic
acid (GLA, 18:3). An elongase then facilitates the addition of
two-carbons to GLA forming DGLA (20:3). DGLA is a substrate
for oxygenases but can be further converted to AA (20:4), the
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FIGURE 1 | Oxylipin biosynthesis and signaling. Oxylipins are
synthesized de novo from polyunsaturated fatty acids (PUFAs) in an
activation dependent manner. Upon cellular activation, cPLA2 hydrolyzes
PUFAs from the lipid membrane generating free PUFAs. Oxygenases (COX,
LOX, and CYP) metabolize free PUFAs into distinct oxylipins. Oxylipins can
diffuse through the plasma membrane and bind GPCRs in the local
environment. Additionally, select oxylipins can activate the transcription
factor PPAR.
most abundant oxylipin precursor, through the addition of a dou-
ble bond by 5 desaturase (Lagarde et al., 2013). The activity of
5 desaturase in human platelets, monocytes and neutrophils is
limited; therefore supplementation with either GLA or DGLA
does not increase AA levels in these cells (de Bravo et al., 1985;
Pullman-Mooar et al., 1990; Barre and Holub, 1992; Chilton et al.,
1996).
The other essential PUFA, ALA (18:3) is converted into the
oxylipin precursors EPA and DHA in a similar manner to the
metabolism of LA (Lagarde et al., 2013; Figure 2). These PUFAs
are esteriﬁed into the sn-2 position of glycerophospholipids and
stored in the lipid membrane providing a potentially high level
of substrate available for de novo production of bioactive lipids
(Lagarde et al., 2013; Figure 3).
FIGURE 2 | Polyunsaturated fatty acid biosynthesis. The essential fatty
acids α-linolenic acid (ALA) and linoleic acid (LA) are metabolized to produce
PUFAs. The initial step is the addition of a double bond to both ALA and LA
to form the respective desaturated products. These desaturated
metabolites are elongated and another desaturase can add a double bond
to these elongated products to produce EPA and AA, respectively. EPA
through a series of enzymes is converted into DHA.
Active cPLA2 is required to hydrolyze PUFAs from the plasma
membrane. The importance of cPLA2 to liberate PUFAs has been
highlighted by a patient who is functionally deﬁcient in cPLA2α
(Reed et al., 2011). Oxylipin productionwas reduced by 95% in the
cPLA2α deﬁcient patient compared to healthy controls following
blood coagulation (Adler et al., 2008). The mechanism by which
free PUFAs trafﬁc to oxygenases is not fully elucidated. Recent data
inplatelets suggests that there are twodifferent pools of AA that can
be selectively utilized by COX-1 and 12(S)-LOX (Holinstat et al.,
2011). Further studies are required to determine how free PUFA
is relegated amongst the various oxygenase isozymes expressed in
different cell types.
Cyclooxygenase, one of the major oxygenases, converts PUFAs
into prostanoids, a subgroup of oxylipins. Prostanoids contain one
or more double bonds and a characteristic ﬁve-membrane ring
structure from carbons 8–12. Ring structures are designated by
different letters from A to K, recently reviewed in detail (Buczyn-
ski et al., 2009). COX converts DGLA,AA, and EPA into series one
prostanoids (PGD1, and PGE1), series two prostanoids (PGD2,
PGE2, PGF2, PGI2, and TxA2) and series three prostanoids (PGE3,
PGD3, and TxA3), respectively (Zivkovic et al., 2012). Prostanoids
can diffuse through the plasma membrane and bind to GPCRs on
the surface of cells in a paracrine or autocrine manner. The num-
ber of double bonds and type of ring structure in a prostanoid
helps establish its prostanoid receptor speciﬁcity. The prostanoid
receptors are divided into ﬁve classes [Prostanoid D receptor (DP),
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FIGURE 3 | PUFA platelet membrane composition and agonist induced
PUFA membrane liberation. The table displays the amount of PUFAs
contained in the platelet membrane of different European populations from
three studies as %weight or %mmol compare to total fatty acids. Columns 1
and 2 of the table represent data from the same study comparing the platelet
composition of individuals from either inland (column 1) or coastal
communities (column 2) in northern Norway. Liberation of PUFAs from the
platelet membrane is achieved in an agonist dependent manner. Platelet
stimulation through a myriad of agonists including thrombin, ADP, and
collagen cause the translocation of cPLA2α to the plasma membrane where it
cleaves PUFAs from the plasma membrane to generate free PUFAs, which
can be metabolized to oxylipins.
Prostanoid E receptor (EP), prostacyclin receptor (IP), thrombox-
ane receptor (TP), and Prostanoid F receptor (FP)] characterized
by their most potent biological ligand, however, there is ligand
cross reactivity with these receptors. For more in depth review on
prostanoids and their receptors, please see Bos et al. (2004).
Lipoxygenases are dioxygenases that catalyze the hydroperoxi-
dation (−OOH) of PUFAs to form oxylipins such as leukotrienes,
lipoxins, and hydroxyeicosatetraenoic acids (HETEs; Strassburg
et al., 2012). Humans express six AA lipoxygenase (ALOX) genes
that can be categorized into four groups of LOX enzymes (3-LOX,
5-LOX, 12-LOX, and 15-LOX) according to the speciﬁc carbon of
AA they oxidize. LOX isozymes are further characterized by tissue
expression and stereospeciﬁcity (R or S; Horn et al., 2013). This
nomenclature, however, can be misleading as LOX isozymes can
oxidize other PUFAs as well as oxidize these PUFAs at carbons
unique from those oxidized on AA. The LOX-derived oxylipins
including HETE and leukotrienes are able to freely pass through
the plasma membrane and signal through GPCRs.
Cytochrome P450 enzymes are a diverse array of membrane
bound, hemeproteins named for their unique absorbance peak
at 450 nm when reduced and bound by carbon monoxide. The
57 CYPs expressed in humans are broken into 18 families and 43
subfamilies based on conserved amino acid identity. CYP nomen-
clature uses a number to identify the family, a letter to categorize
the subfamily and a subsequent number to identify the isozyme,
for example, CYP2C19 (McKinnon et al., 2008). CYP familymem-
bers are best known for their role in xenobiotic metabolism, but
can also metabolize endogenous molecules such as PUFAs to pro-
duce oxylipins. For example, CYP isozymes with hydrolase activity
(CYP4A and CYP4F) generate HETEs while CYPs with epoxyge-
nase activity (CYP2C and CYP2J) generate epoxyeicosatrienoic
acid (EETs) that can be metabolized to dihydroxyeicosatrienoic
acids (DHETs) by soluble epoxide hydrolase (sEH; Fleming, 2001;
Panigrahy et al., 2010). Like other oxylipins, HETEs, EETs, and
DHETs diffuse through the plasma membrane and bind to GPCRs
on the surface of cells as well.
Oxylipins have a myriad of functions that are still being elu-
cidated. Aberrant oxylipin signaling has been shown to lead to
a number of pathologies important to CVD including hyperlipi-
demia, hypertension, thrombosis, and hemostasis (Gleim et al.,
2012). While oxylipins play an important role in a number of
physiological and pathophysiological conditions, this review will
be limited to oxylipin regulation of hemostasis, thrombosis, and
diabetes.
OXYLIPINS IN HEMOSTASIS AND THROMBOSIS
The study of oxylipins and hemostasis began with an anecdotal
observation by Lawrence Craven in the 1940s that tonsillectomy
patients given aspirin gum as an analgesic had an increased risk of
hemorrhage (Miner and Hoffhines, 2007). Spurred by this obser-
vation he began prescribing patients with high risk of a heart
attack low doses of aspirin, he observed no incidence of CVD
related mortality in the approximately 8000 people he treated
with aspirin therapy (Miner and Hoffhines, 2007). Unfortunately,
his studies lacked the rigor required to prove that aspirin did
in fact lower the incidence of myocardial infarction. In the late
1960s, aspirin was shown to reduce platelet aggregation by irre-
versibly inhibiting COX, thus inhibiting the production a potent
prothrombotic oxylipin, thromboxane A2 (Miner and Hoffhines,
2007). It was not until 1989 that the Physicians’ Health Study
provided the scientiﬁc rigor to conclude that aspirin does reduce
the rate of myocardial infarction (Hennekens, 1989). Blocking
secondary mediators of platelet activation such as TxA2 raise
the threshold of platelet activation, but not completely ablate
platelet function. Other than COX metabolites, the functions
of only a few oxylipins have been characterized in platelets
and those that have been characterized still remain controversial
(Lagarde et al., 2010; Ikei et al., 2012). The roles that LOX and
CYPs play in regulating platelet function is less deﬁned but both
enzymes have been shown to signal in other cell types and there-
fore warrant further examination (Brash, 1985; Panigrahy et al.,
2010).
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Cyclooxygenase derived oxylipins are the most well charac-
terized oxylipins in platelets. The activation status of platelets
are regulated by the integration of pro-thrombotic signals by
TxA2 and anti-thrombotic signals through PGI2 (Smyth et al.,
2009). Platelets are producers of prostanoids (TxA2, PGE2, and
PGD2) as well as the targets of prostanoids produced by other
vascular cells such as endothelial cells and leukocytes (PGI2 and
PGE1; Marcus, 1978). One of the primary effects of throm-
boxane is to potentiate platelet aggregation initiated by other
agonists through a positive feedback mechanism. TxA2 signals
through the thromboxane (TPα) receptor expressed on the sur-
face of platelets and increases intracellular calcium (Li et al.,
2010). The primary anti-thrombotic prostanoid identiﬁed thus
far, PGI2, is predominately synthesized by COX-2 in endothelial
cells (Smyth et al., 2009). PGI2, as well as the other anti-
thrombotic prostanoids PGD2, and PGE1, bind to their respective
GPCRs on the surface of the platelet initialing an inhibitory
signal (Marcus, 1978; Smyth et al., 2009; Iyú et al., 2011). The
role of PGE2 is controversial with previous work determin-
ing it had pro- and anti-thrombotic functions. Consistent with
these ﬁndings a recent study showed PGE2 can bind either a
pro-thrombotic (EP3) or anti-thrombotic (EP4) receptor on the
surface of platelets (Iyú et al., 2011). Elucidating the conditions
under which PGE2 is anti-thrombotic could be therapeutically
beneﬁcial.
The effectiveness of low dose aspirin at reducing myocar-
dial infarctions is believed to be due to its ability to inhibit the
production of TxA2 from platelets, with only minimal disrup-
tion of PGI2 from endothelial cells. Consistent with this data
two reports have found that non-steroidal anti-inﬂammatory
drugs (NSAID), COX-1 and COX-2 inhibitors, use decreases the
beneﬁcial effects of aspirin (Kurth et al., 2003; MacDonald and
Wei, 2003). While still controversial, the increased risk in heart
attacks associated with speciﬁc COX-2 inhibitors (celecoxib and
rofecoxib) is hypothesized to be due to a disruption in the bal-
ance of TxA2 and PGI2 creating a pro-thrombotic environment
(Salinas et al., 2007; Cannon and Cannon, 2012; Yeung and Holin-
stat, 2012). Rather than ablate all prostanoid signaling it appears a
more potent therapy is to manipulate the balance of pro and anti-
thrombotic prostanoids. That lesson may be useful when studying
other oxylipins signaling systems in the platelet such as LOX
and CYP.
The ﬁrst LOX, platelet 12(S)-LOX, was discovered in humans
in 1974, yet the role LOX enzymes play in hemostasis and
thrombosis remains controversial (Hamberg and Samuelsson,
1974). 12(S)-LOX is predominantly expressed in platelets and
their precursors, the megakaryocyte. It’s constitutively active
in resting platelets with the majority of the protein located
in the cytosol, and translocates to the lipid membrane dur-
ing platelet activation in a Ca2+-dependent manner (Ozeki
et al., 1999). 12(S)-LOX can oxygenate AA, DGLA, EPA, and
ALA to produce single metabolites 12(S)-HPETE, 12(S)-HPETrE,
12(S)-HPEPE, and 13(S)-HPOTrE, respectively. However, DHA
and GLA are 12-LOX substrates that produce two metabo-
lites. The two DHA-derived metabolites can be divided into a
major product, 14-HDoHE (66%), and a minor, 11-HDoHE
(33%). GLA is also processed by 12-LOX into two unequally
produced products, 10-HOTrE-γ (55%) and 13-HOTrE-γ (44%;
Ikei et al., 2012; Figure 4). Two other PUFAs, EDA or LA,
were incubated with 12-LOX but no oxygenated products were
produced.
Two oxylipins derived from platelet 12(S)-LOX have been
shown to have signaling properties in platelets, 12-HETE and
12-HETrE. 12(S)-HETE contains an extra carbon double bond
between carbon 5 and 6 relative to 12(S)-HETrE, a result of
the double bond conﬁguration in their precursors AA and
DGLA, respectively (Lagarde et al., 2010; Ikei et al., 2012). Platelet
12(S)-LOX processes AA and DGLA at the same rate, how-
ever, since AA is more abundant, 12-HpETE is found to be
the predominate metabolite produced (Figure 4). 12-HpETE is
immediately reduced to 12-HETE by glutathione reductase in
platelets. In response to thrombin or collagen stimulation human
platelets can produce an abundant amount of 12-(S)-HETE
(40–60 ng/4 × 107 platelets; Holinstat et al., 2011; Hammond
and O’Donnell, 2012). 12-(S)-HETE by itself does not cause
platelet aggregation rather it is believed to function in a posi-
tive feedback loop (Setty et al., 1992). The exogenous addition
of 12-(S)-HETE to washed platelets has produced inconsistent
results on platelet aggregation. Previous studies have reported
that 12-(S)-HETE potentiates collagen, adenosine diphosphate
(ADP) and protease-activated receptor (PAR) signaling, while
other studies have shown that 12-(S)-HETE inhibits platelet aggre-
gation in response to AA (Chang et al., 1985; Sekiya et al., 1990,
1991; Setty et al., 1992; Johnson et al., 1998; Katoh et al., 1998;
Lagarde et al., 2010; Yeung and Holinstat, 2011). These differ-
ences could be due to variations in platelet preparation, species
differences or amounts of agonist and 12-(S)-HETE used. Dis-
agreement on the role of 12-(S)-HETE on platelet aggregation
will persist until a deﬁnitive signaling pathway in platelets is deter-
mined. The identiﬁcation of GPR31 as a high afﬁnity GPCR
for 12-(S)-HETE has demonstrated that like leukotrienes, 5-
LOX derived oxylipins, 12-(S)-HETE can also signal via GPCRs
(Murphy and Gijon, 2007; Guo et al., 2011). However, it remains
to be determined if GPR31 is expressed and functional in
platelets.
12(S)-HETrE, the other active platelet 12-(S)-LOXoxylipin,was
just recently identiﬁed in platelets. As previously stated, 12(S)-
HETrE is produced by themetabolism of DGLA by platelet 12-(S)-
LOX. The exogenous addition of 12(S)-HETrE to washed platelets
inhibited PAR-1,ADP, and collagen mediated platelet aggregation.
DGLA and 12(S)-HPETrE, also inhibited clot retraction (Ikei et al.,
2012). The anti-thrombotic effects of DGLA have been known for
over 30 years, however, the mechanism by which DGLA regulates
thrombosis remains unknown. (Kernoff et al., 1977) This data
suggests that platelet 12-(S)-LOX metabolism of DGLA to 12(S)-
HETrE is responsible forDGLAs anti-thrombotic effects. However,
further work is required to conﬁrm the role platelet 12-(S)-LOX
has in the anti-thrombotic effects of DGLA.
Human disease conditions that result in decreased 12-LOX
expression support a role for 12-LOX in thrombosis and hemosta-
sis. Patients with myeloproliferative disorders that have a decrease
in 12-LOX expression have an increase in bleeding and a reduc-
tion in thrombotic complications compared to myeloproliferative
patients with normal 12-LOX levels (Schafer, 1982; Okuma et al.,
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FIGURE 4 | Hemostatically active oxylipins derived from COX and
platelet 12(S)-LOX. Common oxylipin precursors (GLA, DGLA, AA, ALA,
EPA, and DHA) are all substrates for platelet 12(S)-LOX while COX
produces oxylipins predominately from EPA, DGLA, and AA. Both COX
and platelet 12(S)-LOX generate oxylipins that have either prothrombotic
(green box) or anti-thrombotic (red box) signaling properties. Oxylipins
designated with yellow boxes have been reported as pro and
anti-thrombotic in the literature.
1989; Matsuda et al., 1993). Additionally, patients deﬁcient in
the transcription factor, RUNX1 have altered 12-LOX expression
and exhibit a bleeding diathesis (Kaur et al., 2010). While these
results are consistent with 12-LOX playing a role as a regulator of
hemostasis they are complicated by the fact that these patients may
be deﬁcient in other proteins, and the sample size was small.
The challenges of inhibiting 12-LOX speciﬁcally have been the
topic of two recent reviews (Skrzypczak-Jankun et al., 2007; Yeung
and Holinstat, 2011). While the speciﬁcity of previous so-called
12-LOX inhibitors (such as baicalein) have come into question
(Yeung et al., 2012), newer highly selective inhibitors have been
developed (NCTT-956), which conﬁrm the role of 12-LOX in
potentiating platelet activation (Yeung et al., 2012).
Evidence supporting a role for CYPs in regulation of oxylipins
in platelets is lacking. Besides thromboxane synthase, CYP5A1, a
well-known platelet CYP, the role CYPs play in platelet activation
remains relatively unknown. The cyp-oxylipins EET and 20-HETE
have been identiﬁed in platelets for years, but there was no evi-
dence that the enzymes existed in platelets until recently (Zhu
et al., 1995). One group has demonstrated CYP-derived oxylipins
and CYP protein expression in platelets and their megakaryocyte
precursors. The group was able to identify the mRNA and protein
of three CYPs (CYP1A1, 2U1, and 2J2) in human megakaryocyte
[megakaryoblastic leukemia (DAMI) cells]. Additionally, DAMI
cells were able to produce 15 oxylipins, 5-,8-,9-,11-,12-,15-,
20-HETE, 11,12-EET, 14,15-EET, 5,6-DHET, 11,12-DHET, 14,15-
DHET, in the presence of exogenousAA. These results were further
demonstrated by the addition of a CYP inhibitor, SKF-525A that
signiﬁcantly reduced the production of EET, DHET, and HETE
products (Jarrar et al., 2013b). Consistent with the study in DAMI
cells, the same group was able to show that the addition of
exogenous AA to washed platelets produced 17 metabolites which
included the cyp-oxylipins EETs (8,9-, 11,12-, and 14,15-EET) and
20-HETE (Jarrar et al., 2013a). Consistent with DAMI cells mRNA
and protein expression, CYP1A1, 2U1, and 2J2 were detected in
platelets. On the other hand, both the mRNA and protein of two
additional CYPs, 4A11 and 4F2, were detected in platelets, but
were not found in the DAMI cell line. While the role of CYP-
derived oxylipins in platelets is unknown, based on their signaling
properties in other cells, it is hypothesized that they may have
a signaling role in platelets as well. The EET receptor remains
to be identiﬁed, however, evidence suggests that EETs can sig-
nal through GPCRs (Thomson et al., 2012). Follow-up studies
are required to determine whether platelets express cyp-oxylipin
receptors and if so what role they play in the regulation of platelet
aggregation.
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OXYLIPINS AND DIABETES
The alarming increase in diabetes (type 1 and 2) and obesity
has created an escalating global societal concern (Turner et al.,
2013). Substantial evidence indicates that obesity induces a state
of chronic low-grade inﬂammation resulting in insulin resis-
tance (Barton,2008). This obesity-induced inﬂammation exerts its
detrimental effects on multiple cell types in the body including the
insulin producing beta-cells (Asrih and Jornayvaz, 2013). During
the last twodecades, considerable effort has beenmade to elucidate
the molecular factors responsible for obesity-induced inﬂamma-
tion. As a result, it is now well established that obesity-induced
inﬂammation involves the similar set of molecules/signaling
pathways to those involved in a classical inﬂammation includ-
ing 12-LOX derived oxylipins. 12-LOX and its oxylipins are
now known to play an important role in both adipogenesis as
well as the destruction of beta-cells, both key pathologies in
diabetes.
Studies of adipogenesis have revealed its dependence on an
exogenous supply of free PUFAs and LOX-derived oxylipins
to facilitate activation of PPAR (Madsen et al., 2003) in early
adipocyte differentiation (Barak et al., 1999), which is evidenced
by treatment of 3T3-L1 pre-adipocytes with either non-speciﬁc
or speciﬁc 12-LOX inhibitors (Yu et al., 1995). In addition, this
role appears to be speciﬁc to the epidermal-derived 12-LOX,
as the platelet- and leukocyte-derived 12-LOXs are expressed at
very low levels in the pre-adipocytes and early differentiated
adipocytes. Additionally, no adipogenic defects were observed
in leukocyte-12-LOX or platelet-12-LOX deﬁcient mice (Kozak
et al., 2002; Hallenborg et al., 2010). However, Leukocyte-12-LOX
(12/15-LOX) appears to be a signiﬁcant player in modulating
adipocyte function in vivo in diet-induced mouse models of
obesity. In a comparative study of 12/15-LOX knockout mice
with C57BL6/J mice fed either a standard chow or high-fat
“Western” type diet revealed that 12/15-LOX is the primary
enzyme generating the 12(S)-HETE products under obese condi-
tions (Nunemaker et al., 2008). The increased 12/15-LOX activity
coincided with increased inﬂammation both systemically and
in epididymal adipose tissue. Fewer incidences of macrophage
inﬁltration and activation were observed in the epididymal adi-
pose fat pads from 12/15-LOX knockout mice when fed the
Western diet. Moreover, 12/15-LOX knockout mice also showed
protection fromdeveloping insulin resistance andmaintainednor-
mal adiponectin, an anti-inﬂammatory adipose-derived cytokine
(adipokine; Sears et al., 2009). All this data indicates that 12/15-
LOX activation under diet-induced obese conditions plays a
signiﬁcant role in mediating inﬂammation via ensuing adipocyte
dysfunction. Chakrabarti et al. (2009) performed a detailed eval-
uation of the role of 12/15-LOX-derived products in adipocytes.
In their experiments, direct addition of 12(S)-HETE and 12(S)-
HPETE to differentiated 3T3-L1 adipocytes resulted in increased
inﬂammatory cytokines, tumor necrosis factor-alpha (TNF-α),
monocyte chemotactic protein-1 (MCP-1), interleukin (IL)-6,
and IL-12p40, and a decreased expression of adiponectin. In
addition, these products induced insulin resistance as measured
by a decrease in insulin-mediated activation of key insulin-
signaling proteins, such as Akt and insulin receptor substrate-1.
Furthermore, a free fatty acid component of high-fat diets,
palmitic acid was able to induce 12/15-LOX expression in 3T3-L1
adipocytes, demonstrating that products of 12/15-LOX pathway
can directly impair adipocyte function in a fatty acid surplus
environment.
Upregulated 12-LOX activity or expression have also been
implicated in the functional loss of insulin secretion or produc-
tion in beta-cells of the pancreatic islets, which are important
regulator of blood glucose (Ma et al., 2010). Primarily, the loss
or defect in insulin production or release from the beta-cell is
caused by aberrant inﬂammatory response that results in a hyper-
glycemic state in the body of type 1 and 2 diabetes patients (Nauck,
2011). Multiple gene-based knockout studies and targeted protein
knockdown approaches have established the importance of 12-
LOX role in islet function. Insulin resistance and impairment in
islet function that develops on a high-fat diet were prevented in
leukocyte-12-LOX (12/15-LOX) knockout mice, suggesting that
12/15-LOX activity is relevant to type 2 diabetes, and to beta-
cell dysfunction in obese states (Laybutt et al., 2002). Additionally,
diabetic Zucker fatty rats that have a defect in insulin secretion
have elevated 12-LOX expression/activity, further supporting a
role for 12-LOX in the pathogenesis of type 2 diabetes (Tokuyama
et al., 1995). A direct role of pro-inﬂammatory cytokines in
stimulating 12-LOX activity is further supported by observa-
tions of cytokine-induced production of 12-HETE in both islets
and beta-cell lines (Han et al., 2002). Furthermore, the addi-
tion of 12-LOX products (12-HETE and 12-HPETE) to human
islets resulted in a decrease in glucose-stimulated insulin secre-
tion associated with a decrease in islet viability (Persaud et al.,
2007), and a partial restoration in glucose-stimulated insulin
secretion if 12HETE was combined with lisofylline, an inhibitor
of IL-12 signaling. Collectively these data support a predicted
role of IL-12 in mediating the immune damage caused by the
12-LOX pathway (Simonsen et al., 1987; Vidgren et al., 1997;
Vognild et al., 1998).
CONCLUSION
Substantial gains have beenmade in our understanding of oxylipin
signaling systems since their discovery 50 years ago. The recent
advancements in mass spectrometry have led to a resurgence in
oxylipin research. This technology has allowed for the accurate
and reproducible measurement of over a 100 different oxylipins
at the nanomolar level during cellular stimulation or complex
signaling events such as blood coagulation (Strassburg et al., 2012).
While these lipidomics techniques can identify the vast number of
unique oxylipins produced during cellular stimulation, they do
not address the biological function of the oxylipins generated. The
level of resolution enabled by recent advances in lipidomics gives
researchers the ability to discover novel oxylipins in an unbiased
approach and measure oxylipin proﬁles from healthy individuals
as well as those suffering from a variety of pathophysiological
conditions.
The identiﬁcation of novel oxylipins has outpaced the abil-
ity of researchers to characterize their biological functions. The
characterization of individual oxylipin signaling is not a trivial
matter. Further, multiple oxylipins are synthesized in response to
the same agonist making it difﬁcult to attribute the ﬁnal cellular
response to any one particular metabolite. Techniques to examine
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the role of individual oxylipins are not without their limitations,
which is one of the reasons for much of the controversy in the
ﬁeld. Together a combination of lipidomics, genetics, and phar-
macological approaches can approximate the role of an oxylipin
in the cell and surrounding tissue. Finally, to identify the under-
lying mechanism regulated by an oxylipin of interest, its correlate
receptor must be elucidated.
These new techniques can be used to identify potential
biomarkers and therapeutic targets by identifying differences in
the oxylipin proﬁles of healthy subjects andpatientswith a number
of cardiovascular deﬁciencies including those with type 2 diabetes
mellitus. This approach can be used to proﬁle changes in the abso-
lute magnitude of oxylipins or measure the ratios of oxylipins with
juxtaposed signaling properties. One of the principle limitation to
applying lipidomics techniques to identiﬁcationof biomarkers and
as a means to determine treatment is the availability of fresh sam-
ples. Thus, this technique is primarily being applied to the CVDs
due to the ability to measure the oxylipin levels from serum and
hematopoietic cells.
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